Development of the celiac disease symptom diary version 2.1© (CDSD 2.1©) patient-reported outcome measure
CDSD 2.1<sup>©</sup> is a content-valid patient-reported outcome measure developed in accordance with best practices and regulatory guidance. A thorough exploration of the psychometric properties of CDSD 2.1<sup>©</sup> for both adult and adolescent participants with CeD is ongoing to support utilization in clinical trials.
Authors
- Daniel A. Leffler (ORCID: https://orcid.org/0000-0002-0750-3386)
- Susan Martin (ORCID: https://orcid.org/0000-0002-9594-5036)
- Sarah Acaster (ORCID: https://orcid.org/0000-0003-1025-2546)
- Kellee Howard (ORCID: https://orcid.org/0009-0009-8608-3161)
- Lisa M. Meckley (ORCID: https://orcid.org/0000-0002-4791-4294)
- Ciarán P. Kelly (ORCID: https://orcid.org/0000-0002-8216-1240)
- Daniel C. Adelman (ORCID: https://orcid.org/0000-0002-0470-3235)
- Sarah Clifford (ORCID: https://orcid.org/0000-0002-6811-4691)
- sonal ghura (ORCID: https://orcid.org/0009-0004-8615-9297)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Lloyd's (GB)
- RTI Health Solutions (US)
- Imperial Consultants (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Takeda (United States) (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Quality of Life Research
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1007/s11136-024-03799-6
- Citations
- 2
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- Takeda Pharmaceuticals U.S.A.